158 related articles for article (PubMed ID: 11796334)
1. Evaluation of a cyclic GMP-dependent protein kinase inhibitor in treatment of murine toxoplasmosis: gamma interferon is required for efficacy.
Nare B; Allocco JJ; Liberator PA; Donald RG
Antimicrob Agents Chemother; 2002 Feb; 46(2):300-7. PubMed ID: 11796334
[TBL] [Abstract][Full Text] [Related]
2. Toxoplasma gondii cyclic GMP-dependent kinase: chemotherapeutic targeting of an essential parasite protein kinase.
Donald RG; Allocco J; Singh SB; Nare B; Salowe SP; Wiltsie J; Liberator PA
Eukaryot Cell; 2002 Jun; 1(3):317-28. PubMed ID: 12455981
[TBL] [Abstract][Full Text] [Related]
3. Characterization of Plasmodium falciparum cGMP-dependent protein kinase (PfPKG): antiparasitic activity of a PKG inhibitor.
Diaz CA; Allocco J; Powles MA; Yeung L; Donald RG; Anderson JW; Liberator PA
Mol Biochem Parasitol; 2006 Mar; 146(1):78-88. PubMed ID: 16325279
[TBL] [Abstract][Full Text] [Related]
4. IL-10 is not required to prevent immune hyperactivity during memory responses to Toxoplasma gondii.
Wille U; Nishi M; Lieberman L; Wilson EH; Roos DS; Hunter CA
Parasite Immunol; 2004 May; 26(5):229-36. PubMed ID: 15491472
[TBL] [Abstract][Full Text] [Related]
5. A role for coccidian cGMP-dependent protein kinase in motility and invasion.
Wiersma HI; Galuska SE; Tomley FM; Sibley LD; Liberator PA; Donald RG
Int J Parasitol; 2004 Mar; 34(3):369-80. PubMed ID: 15003497
[TBL] [Abstract][Full Text] [Related]
6. [Rudolf-Virchow Prize 1998. Award lecture. Toxoplasmosis: a model infection for studying systemic and intracerebral immune reactions].
Deckert-Schlüter M
Verh Dtsch Ges Pathol; 1998; 82():9-22. PubMed ID: 10095413
[TBL] [Abstract][Full Text] [Related]
7. Two old drugs, NVP-AEW541 and GSK-J4, repurposed against the Toxoplasma gondii RH strain.
Liu S; Wu M; Hua Q; Lu D; Tian Y; Yu H; Cheng L; Chen Y; Cao J; Hu X; Tan F
Parasit Vectors; 2020 May; 13(1):242. PubMed ID: 32393321
[TBL] [Abstract][Full Text] [Related]
8. C5aR1 Activation Drives Early IFN-γ Production to Control Experimental
Briukhovetska D; Ohm B; Mey FT; Aliberti J; Kleingarn M; Huber-Lang M; Karsten CM; Köhl J
Front Immunol; 2020; 11():1397. PubMed ID: 32733463
[No Abstract] [Full Text] [Related]
9. Bumped kinase inhibitor 1294 treats established Toxoplasma gondii infection.
Doggett JS; Ojo KK; Fan E; Maly DJ; Van Voorhis WC
Antimicrob Agents Chemother; 2014 Jun; 58(6):3547-9. PubMed ID: 24687502
[TBL] [Abstract][Full Text] [Related]
10. RabGDIα is a negative regulator of interferon-γ-inducible GTPase-dependent cell-autonomous immunity to Toxoplasma gondii.
Ohshima J; Sasai M; Liu J; Yamashita K; Ma JS; Lee Y; Bando H; Howard JC; Ebisu S; Hayashi M; Takeda K; Standley DM; Frickel EM; Yamamoto M
Proc Natl Acad Sci U S A; 2015 Aug; 112(33):E4581-90. PubMed ID: 26240314
[TBL] [Abstract][Full Text] [Related]
11. NADPH Oxidase and Guanylate Binding Protein 5 Restrict Survival of Avirulent Type III Strains of Toxoplasma gondii in Naive Macrophages.
Matta SK; Patten K; Wang Q; Kim BH; MacMicking JD; Sibley LD
mBio; 2018 Aug; 9(4):. PubMed ID: 30154263
[TBL] [Abstract][Full Text] [Related]
12. Involvement of Host Defense Mechanisms against Toxoplasma gondii Infection in Anhedonic and Despair-Like Behaviors in Mice.
Mahmoud ME; Fereig R; Nishikawa Y
Infect Immun; 2017 Apr; 85(4):. PubMed ID: 28138019
[No Abstract] [Full Text] [Related]
13. Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of Toxoplasmosis.
Vidadala RS; Rivas KL; Ojo KK; Hulverson MA; Zambriski JA; Bruzual I; Schultz TL; Huang W; Zhang Z; Scheele S; DeRocher AE; Choi R; Barrett LK; Siddaramaiah LK; Hol WG; Fan E; Merritt EA; Parsons M; Freiberg G; Marsh K; Kempf DJ; Carruthers VB; Isoherranen N; Doggett JS; Van Voorhis WC; Maly DJ
J Med Chem; 2016 Jul; 59(13):6531-46. PubMed ID: 27309760
[TBL] [Abstract][Full Text] [Related]
14. Secretory Microneme Proteins Induce T-Cell Recall Responses in Mice Chronically Infected with Toxoplasma gondii.
Saraav I; Wang Q; Brown KM; Sibley LD
mSphere; 2019 Feb; 4(1):. PubMed ID: 30814319
[TBL] [Abstract][Full Text] [Related]
15. Indoleamine 2,3-Dioxygenase Activity During Acute Toxoplasmosis and the Suppressed T Cell Proliferation in Mice.
Ufermann CM; Domröse A; Babel T; Tersteegen A; Cengiz SC; Eller SK; Spekker-Bosker K; Sorg UR; Förster I; Däubener W
Front Cell Infect Microbiol; 2019; 9():184. PubMed ID: 31231617
[No Abstract] [Full Text] [Related]
16. Histone deacetylase inhibitor MS-275 augments expression of a subset of IFN-γ-regulated genes in Toxoplasma gondii-infected macrophages but does not improve parasite control.
Sumpf K; Nast R; Downie B; Salinas G; Lüder CGK
Exp Parasitol; 2017 Sep; 180():45-54. PubMed ID: 28189488
[TBL] [Abstract][Full Text] [Related]
17. Stage conversion of Toxoplasma gondii RH parasites in mice by treatment with atovaquone and pyrrolidine dithiocarbamate.
Djurković-Djaković O; Nikolić A; Bobić B; Klun I; Aleksić A
Microbes Infect; 2005 Jan; 7(1):49-54. PubMed ID: 15716077
[TBL] [Abstract][Full Text] [Related]
18. Treatment of mice with S4B6 IL-2 complex prevents lethal toxoplasmosis via IL-12- and IL-18-dependent interferon-gamma production by non-CD4 immune cells.
Kupz A; Pai S; Giacomin PR; Whan JA; Walker RA; Hammoudi PM; Smith NC; Miller CM
Sci Rep; 2020 Aug; 10(1):13115. PubMed ID: 32753607
[TBL] [Abstract][Full Text] [Related]
19. Effect of Nigella sativa oil on experimental toxoplasmosis.
Mady RF; El-Hadidy W; Elachy S
Parasitol Res; 2016 Jan; 115(1):379-90. PubMed ID: 26446086
[TBL] [Abstract][Full Text] [Related]
20. Phytoecdysteroids as modulators of the Toxoplasma gondii growth rate in human and mouse cells.
Dzitko K; Grzybowski MM; Pawełczyk J; Dziadek B; Gatkowska J; Stączek P; Długońska H
Parasit Vectors; 2015 Aug; 8():422. PubMed ID: 26272689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
